Products for Research Use Only

Ibipinabant

CAT: 0804-HY-14791-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14791-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a Ki of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (Ki=7943 nM) . Ibipinabant can be used for the research of obesity and diabetic[1][2][3].
CAS Number
464213-10-3
Product Name Alternative
SLV319; BMS-646256
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Cannabinoid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ibipinabant.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
C/N=C(N1N=C(C2=CC=C(Cl)C=C2)[C@@H](C3=CC=CC=C3)C1)\NS(=O)(C4=CC=C(Cl)C=C4)=O
Molecular Formula
C23H20Cl2N4O2S
Molecular Weight
487.40
Precautions
H315, H319, H335
References & Citations
[1]Lange JHM, et, al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB (1) cannabinoid receptor antagonists. J Med Chem. 2004 Jan 29;47 (3) :627-43.|[2]Tam J, et, al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012 Aug 8;16 (2) :167-79.|[3]Rohrbach K, et, al. Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab. 2012 Jun;14 (6) :555-64.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
CB1; CB2